Phenoxodiol, an experimental anticancer drug, shows potent antiangiogenic properties in addition to its antitumour effects

International Journal of Cancer

Volumn 118, Issue 10, 2006, Pages 2412-2420

  Gamble, Jennifer R ^a,b,d   Xia, Pu ^a   Hahn, Christopher N ^a   Drew, Jenny J ^a   Drogemuller, Christopher J ^a   Brown, David ^c   Vadas, Mathew A ^a,b  

^a INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c Novogen Limited   (Australia)

^d NONE   (Australia)

Author keywords

Angiogenesis; Cancer; Flavonoids; Sphingosine kinase

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GELATINASE A; GENISTEIN; INTERLEUKIN 1; INTERLEUKIN 8; ISOFLAVONE DERIVATIVE; NATURAL PRODUCT; PHENOXODIOL; SPHINGOSINE KINASE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL ACTIVATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; ENDOTHELIUM CELL; ENZYME INHIBITION; HUMAN; HUMAN CELL; INFLAMMATION; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; TUMOR GROWTH;

ANIMALS; CAPILLARIES; CELL MOVEMENT; CELL PROLIFERATION; ENDOTHELIAL CELLS; FEMALE; HUMANS; INFLAMMATION; ISOFLAVONES; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); UMBILICAL CORD;

EID: 33646426132     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21682     Document Type: Article

References (54)

1. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;10:737-44.
2. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989;6219:58-61.
3. Grunstein J, Roberts WG, Mathieu-Costello O, Hanahan D, Johnson RS. Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res 1999;7:592-8.
4. Matsukawa Y, Marui N, Sakai T, Satomi Y, Yoshida M, Matsumoto K, Nishino H, Aoike A. Genistein arrests cell cycle progression at G2-M. Cancer Res 1993;53:1328-31.
5. Constantinou A, Huberman E. Genistein as an inducer of tumour cell differentiation: possible mechanisms of action. Proc Soc Exp Biol Med 1995;208:109-115.
6. Constantinou A, Kiguchi K, Huberman E. Induction of differentiation and DNA strand breakage in human HL-60 and K-562 leukemia cells by genistein. Cancer Res 1990;50:2618-24.
7. Watanabe T, Kondo K, Oishi M. Induction of in vitro differentiation of mouse erythroleukemia cells by genistein, an inhibitor of tyrosine protein kinases. Cancer Res 1991;51:764-8.
8. Uckun FM, Evans WE, Forsyth CJ, Waddick KG, Ahlgren LT, Chelstrom LM, Burkhardt A, Bolen J, Myers DE. Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases. Science 1995;267:886-91.
9. Tragonos F, Ardelt B, Halko N, Bruno S, Darzynkiewicz Z. Effects of genistein on the growth and cell cycle progression of normal human lymphocytes and human leukemic MOLT-4 and HL-60 cells. Cancer Res 1992;52:6200-08.
10. Peterson G, Barnes S. Genistein inhibition of the growth of human breast cancer cells: independence from estrogen receptors and the multi-drug resistance gene. Biochem Biophys Res Commun 1991;179:661-7.
11. Fotsis T, Pepper M, Adlercreutz H, Hase T, Montesano R, Schweigerer L. Genistein, a dietary ingested isoflavonoid, inhibits cell proliferation and in vitro angiogenesis. J Nutr 1995;125:790S-797S.
12. Bergan R, Kyle E, Nguyen P, Trepel J, Ingui C, Neckers L. Genistein-stimulated adherence of prostate cancer cells is associated with the binding of coal adhesion kinase to β-1-integrin. Clin Exp Metastasis 1996;14:389-98.
13. Schweigerer L, Christeleit K, Fleischmann G, Adlercreutz H, Wahala K, Hase T, Schwab M, Ludwig R, Fotsis T. Identification in human urine of a natural growth inhibitor for cells derived from solid paediatric tumours. Fur J Clin Invest 1992;22:260-4.
14. Kamsteeg M, Rutherford T, Sapi E, Hanczaruk B, Shahabi S, Flick M, Brown D, Mor G. Phenoxodiol-an isoflavon analogue-induces apoptosis in chemo-resistant ovarian cancer cells. Oncogene 2003;22:2611-20.
15. Olivera A, Spiegel S. Sphingosine-1-phosphate as second messenger in cell proliferation induced by PDGF and FCS mitogens. Nature 1993;365:557-60.
16. Zhang H, Desai NN, Olivera A, Seki T, Brooker G, Spiegel S. Sphingosine-1-phosphate, a novel lipid, involved in cellular proliferation. J Cell Biol 1991;114:155-67.
17. Van Brocklyn JR, Lee MJ, Menzeleev R, Olivera A, Edsall L, Cuvillier O, Thomas DM, Coopman PJ, Thangada S, Liu CH, Hla T, Spiegel S. Dual actions of sphingosine-1-phosphate: extracellular through the Gi-coupled receptor Edg-1 and intracellular to regulate proliferation and survival. J Cell Biol 1998;142:229-40.
18. Olivera A, Kohama T, Edsall L, Nava V, Cuvillier O, Poulton S, Spiegel S. Sphingosine kinase expression increases intracellular sphingosine-1-phosphate and promotes cell growth and survival [In Process Citation]. J Cell Biol 1999;147:545-58.
19. Hong G, Baudhuin LM, Xu Y. Sphingosine-1-phosphate modulates growth and adhesion of ovarian cancer cells. FEBS Lett 1999;460:513-18.
20. Xia P, Gamble JR, Wang L, Pitson SM, Moretti PAB, Wattenberg BW, D'Andrea RJ, Vadas MA. An oncogenic role of sphingosine kinase. Current Biol 2000;10:1527-30.
21. Shu X, Wu W, Mosteller RD, Broek D. Sphingosine kinase mediates vascular endothelial growth factor-induced activation of ras and mitogen-activated protein kinases. Mol Cell Biol 2002;22:7758-68.
22. Nava VE, Hobson JP, Murthy S, Milstien S, Spiegel S. Sphingosine kinase type 1 promotes estrogen-dependent tumorigenesis of breast cancer MCF-7 cells. Exp Cell Res 2002;281:115-27.
23. Sukocheva OA, Wang L, Albanese N, Pitson SM, Vadas MA, Xia P. Sphingosine kinase transmits oestrogen signaling in human breast cancer cells. Mol Endocrinol 2003;17:2002-4.
24. French KJ, Schrecengost RS, Lee BD, Zhuang Y, Smith SN, Eberly JL, Yun JK, Smith CD. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res 2003;63:5962-9.
25. Xia P, Gamble JR, Rye K-A, Wang L, Hii CST, Cockerill P, Khew-Goodall Y, Bert AG, Barter PJ, Vadas MA. Tumour necrosis factor-α induces adhesion molecule expression through the sphingosine kinase pathway. Proc Natl Acad Scie USA 1998;95:14196-201.
26. Xia P, Wang L, Gamble JR, Vadas MA. Activation of sphingosine kinase by tumour necrosis factor-α inhibits apoptosis in human endothelial cells. J Biol Chem 1999;274:34499-505.
27. Lee OH, Kim YM, Lee YM, Moon EJ, Lee DJ, Kim JH, Kim KW, Kwon YG. Sphingosine-1-phosphate induces angiogenesis: its angiogenic action and signaling mechanism in human umbilical vein endothelial cells. Biochem Biophys Res Commun 1999;264:743-50.
28. English D, Kovala AT, Welch Z, Harvey KA, Siddiqui RA, Brindley DN, Garcia JG. Induction of endothelial cell chemotaxis by sphingosine 1-phosphate and stabilization of endothelial monolayer barrier function by lysophosphatidic acid, potential mediators of hematopoietic angiogenesis. J Hematother Stem Cell Res 1999;8:627-34.
29. Ancellin N, Colmont C, Su J, Li Q, Mittereder N, Chae SS, Stefansson S, Liau G, Hla T. Extracellular export of sphingosine kinase-1 enzyme. Sphingosine 1-phosphate generation and the induction of angiogenic vascular maturation. J Biol Chem 2002;277:6667-75.
30. Xia P, Vadas MA, Rye KA, Barter PJ, Gamble JR. High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway. A possible mechanism for protection against atherosclerosis by HDL. J Biol Chem 1999;274:33143-7.
31. Liu Y, Wada R, Yamashita T, Mi Y, Deng C-X, Hobson JP, Rosenfeldt HM, Nava VE, Chae S-K, Lee M-J, Liu CH, Hla T, et al. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest 2000;106:951-61.
32. Limaye V, Li X, Hahn C, Xia P, Berndt MC, Vadas MA, Gamble TR. Sphingosine kinase-1 enhances endothelial cell survival through a PECAM-1 dependent activation of P13K/Akt and regulation of Bcl-2 family members. Blood 2005;105:3169-77.
33. Gamble JR, Matthias LJ, Meyer G, Kaur P, Russ G, Faull R, Berndt MC, Vadas MA. Regulation of in vitro capillary tube formation by anti-integrin antibodies. J Cell Biol 1993;121:931-43.
34. Leavesley DI, Schwartz MA, Rosenfeld M, Cheresh DA. Integrin β- and β3-mediated endothelial cell migration is triggered through distinct signaling mechanisms. J Cell Biol 1993;121:163-70.
35. Gamble J, Meyer G, Noack L, Furze J, Matthias L, Kovach N, Harlan J, Vadas MA. β1 integrin activation inhibits in vitro tube formation: effects on cell migration, vacuole coalescence and lumen formation. Endothelium 1999;7:23-34.
36. McCarty MF, Baker CH, Bucana CD, Fidler IJ. Quantitative and qualitative in vivo angiogenesis assay. Int J Oncol 2002;21:5-10.
37. Stoeltzing O, Ahmad SA, Liu W, McCarty MF, Wey JS, Parikh AA, Fan F, Reinmuth N, Kawaguchi M, Bucana CD, Ellis LM. Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumours. Cancer Res 2003;63:3370-7.
38. Naglich JG, Jure-Kunkel M, Gupta E, Fargnoli J, Henderson AJ, Lewin AC, Talbott R, Baxter A, Bird J, Savopoulos R, Wills R, Kramer RA, et al. Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291. Cancer Res 2001;61:8480-5.
39. Haas TL, Davis SJ, Madri JA. Three-dimensional type I collagen lattices induce coordinate expression of matrix metalloproteinases MT1-MMP and MMP-2 in microvascular endothelial cells. J Biol Chem 1998;273:3604-10.
40. Fang J, Shing Y, Wiederschain D, Van L, Butterfield C, Jackson G, Harper J, Tamvakopoulos G, Moses MA. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumour model. Proc Natl Acad Sci USA 2000;97:3884-9.
41. Salven P, Hattori K, Heissig B, Rafii S. Interleukin-1α promotes angiogenesis in vivo via VEGFR-2 pathway by inducing inflammatory cell VEGF synthesis and secretion. FASEB J 2002;16:1471-3.
42. Klein S, de Fougerolles AR, Blaikie P, Khan L, Pepe A, Green CD, Koteliansky V, Giancotti FG. α5-β1-integrin activates and NF-κB-dependent program of gene expression important for angiogenesis and inflammation. Mol Cell Biol 2002;22:5912-22.
43. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, Shibuya M, Fukami Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 1987;262:5592-5.
44. Constantinou A, Mehta R, Runyan C, Rao K, Vaughan A, Moon R. Flavonoids as DNA topoisomerase antagonists and poisons: structure-activity relationships. J Nat Prod 1995;58:217-25.
45. Markovits J, Linassier C, Fosse P, Couprie J, Pierre J, Jacquemin-Sablon A, Saucier JM, Le Pecq JB, Larsen AK. Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II. Cancer Res 1989;49:5111-17.
46. Heck MM, Earnshaw WC. Topoisomerase II: a specific marker for cell proliferation. J Cell Biol 1986;103:2569-81.
47. Constantinou AI, Husband A. Phenoxodiol (2H-1-benzopyran-7-0,1,3-(4- hydroxyphenyl), a novel isoflavone derivative, inhibits DNA topoisomerase II by stabilizing the cleavable complex. Anticancer Res 2002;22,2581-5.
48. Nava VE, Cuvillier O, Edsall LC, Kimura K, Milstein S, Gelmann EP, Spiegel S. Sphingosine enhances apoptosis of radiation-resistant prostate cancer cells. Cancer Res 2000;60:4468-74.
49. Cuvillier O, Prianov G, Kleuser B, Vanek PG, Coso O, Gutkind S, Spiegel S. Suppression of ceramide mediated programme cell death by sphingosine-1- phosphate. Nature (London) 1996;381:800-03.
50. Wu W, Shu X, Hovsepyan H, Mosteller RD, Broek D. VEGF receptor expression and signaling in human bladder tumors. Oncogene 2003;22:3361-70.
51. Shu X, Wu W, Mosteller RD, Broek D. Sphingosine kinase mediates vascular endothelial growth factor-induced activation of ras and mitogen-activated protein kinases. Mol Cell Biol 2002;22:7758-68.
52. Li Y, Sarkar FH. Inhibition of nuclear factor κB activation in PC3 cells by genistein is mediated via Akt signaling pathway. Clin Cancer Res 2002;8:2369-77.
53. Gong L, Nedeljkovic-Kurepa A, Sarkar FH. Inactivation of NF-κB by genistein is mediated via Akt signaling pathway in breast cancer cells. Oncogene 2003;22:4702-9.
54. Rakesh KJ. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.